Navigation Links
Cytokinetics Reports Additional Clinical Trials Data for Ispinesib

all of these trials; patients remain on treatment in the renal cell cancer trial. Data from the other trials have already been reported.

The NCI has completed patient treatment in a Phase I clinical trial designed to evaluate the safety, tolerability and pharmacokinetics of ispinesib on an alternative dosing schedule in patients with advanced solid tumors that have failed to respond to all standard therapies; data from this trial have already been reported. The NCI is continuing patient enrollment in a Phase I clinical trial designed to evaluate the safety, tolerability and pharmacokinetics of ispinesib on an alternative dosing schedule in patients with relapsed or refractory acute leukemia, chronic myelogenous leukemia in blast crisis, or advanced myelodysplastic syndromes. Data from this trial are expected in 2007.

Background on Mitotic Kinesin Inhibitors

Since their introduction over 40 years ago, anti-mitotic drugs (taxanes and vinca alkaloids) have advanced the treatment of cancer and are commonly used for the treatment of several tumor types. However, these drugs have demonstrated limited treatment benefit against certain cancers. In addition, these drugs target tubulin, a cytoskeletal protein involved not only in mitosis and cell proliferation, but also in other important cellular functions. Inhibition of these other cellular functions produces dose-limiting toxicities such as peripheral neuropathy, an impairment of peripheral nervous system function. Neuropathies are thought to result when these drugs interfere with the dynamics of microtubule filaments that are responsible for the long-distance transport of important cellular components within nerve cells.

Mitotic kinesins are essential to mitosis, and, unlike tubulin, appear to have no role in other cellular functions. Cytokinetics believes that drugs that inhibit KSP and CENP-E and other mitotic kinesins may represent the next generation of anti-mitotic cancer drugs
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Cytokinetics Announces Non-clinical Data to be Presented at the 2007 AACR Annual Meeting
2. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
3. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
4. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
5. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
6. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
7. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
8. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
9. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
10. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
11. Affymax Reports Phase 2 Clinical Dose Ranging Results of Once-Per-Month Hematide for the Treatment of Anemia
Post Your Comments:
(Date:7/3/2015)... MUMBAI, India , July 4, 2015 /PRNewswire/ ... médicale continue cible les épidémies que sont l,hypertension, ... centrale et du Sud-Est, par l,intermédiaire de plateformes ... ces maladies.      (Photo: http://photos.prnewswire.com/prnh/20150630/227090 ... Prendre en charge le diabète en ligne , ...
(Date:7/3/2015)... MUMBAI , July 3, 2015 /PRNewswire/ ... gab heute bekannt, vorbehaltlich bestimmter Abschlussbedingungen eine ... Russland erworben zu haben. Mit dieser Übernahme ... der mit einem Umsatz von 765 Mrd. ... größten Pharmamärkten der Welt gehörte (IMS Health). ...
(Date:7/2/2015)... HILL, N.C. , July 2, 2015 /PRNewswire/ ... own employees to capture critical product and market ... are many benefits to employee-based studies, it is ... leverage their own internal employees to capture critical ... study by benchmarking firm, Best Practices, LLC, most ...
Breaking Medicine Technology:Lutter contre trois maladies chroniques majeures en Asie centrale et du Sud-Est grâce à la formation médicale 2Lutter contre trois maladies chroniques majeures en Asie centrale et du Sud-Est grâce à la formation médicale 3Lupin übernimmt Biocom aus Russland 2Lupin übernimmt Biocom aus Russland 3Leveraging Employee Insights to Produce Cutting-Edge Market Research 2
... PITTSBURGH, Sept. 21 Mylan Inc. (Nasdaq: ... the U.S. District Court for the District of New ... selling or shipping or otherwise launching … or importing" ... Paxil CR, Paroxetine Hydrochloride (HCl) Extended-release (ER) Tablets, 12.5 ...
... Sept. 21 More than one in three ... as prescribed, stating that they have done so on average ... physicians estimate that in reality this number could be as ... Patients and Physicians in Insulin Therapy (GAPP™) survey, released today ...
Cached Medicine Technology:New Global Survey Reveals Over One in Three Patients Fail to Take Insulin as Prescribed 2New Global Survey Reveals Over One in Three Patients Fail to Take Insulin as Prescribed 3
(Date:7/5/2015)... ... July 05, 2015 , ... Doctors at the Swedish Cancer Institute in Seattle, ... day change the outlook for people with pleural mesothelioma. Surviving Mesothelioma has just posted ... report that five mesothelioma patients treated with 25Gy of radiation over five days just ...
(Date:7/4/2015)... ... July 04, 2015 , ... Tyler ... recognition of technical sales expertise from the North American Board of Certified Energy ... is the most highly respected and well established national certification organization for renewable ...
(Date:7/3/2015)... (PRWEB) , ... July 03, 2015 , ... Scientists at ... susceptible to mesothelioma with even minimal asbestos exposure. Click here to read the ... the University of Hawaii Cancer Center, Cedars Sinai Medical Center, and New York University ...
(Date:7/3/2015)... ... 2015 , ... Smoothies are all the rage right now and all you ... ingredients. Aurora Natural is proud to introduce a new line of all natural products ... vitamins and minerals! , Aurora is offering a variety of blends and stand-alone items ...
(Date:7/3/2015)... ... ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh in Abilene, Texas, ... and expose popular lies regarding proper relationships according to the bible. , ... the core of the subject by explaining why certain types of sexual relationships are ...
Breaking Medicine News(10 mins):Health News:New Mesothelioma Study Calls IMRT/Surgery Combo “Innovative and Promising”, According to Surviving Mesothelioma 2Health News:Local Solar Professional Earns Industry's Most Prestigious Certification 2Health News:Local Solar Professional Earns Industry's Most Prestigious Certification 3Health News:Study Finds Small Amounts of Asbestos May Trigger Mesothelioma in People with Genetic Mutation, According to Surviving Mesothelioma 2Health News:Aurora Product, Inc. Announces An Original New Line: Smoothie Fixins’ 2Health News:Yisrayl Hawkins Explains What the Bible Really Says about Sex in New Publication This Week 2
... physically abused in Germany. Many more, some 12,000 to 13,000, ... statistics, but in fact a high proportion of unreported cases ... Deutsches rzteblatt International contains an article in which Winfried ... present the findings of their representative survey of a sample ...
... Men and women infected with HIV reduced the risk of ... antiretroviral medicines when their immune systems were relatively healthy, according ... National Institute of Allergy and Infectious Diseases (NIAID), part of ... known as HPTN 052, was slated to end in 2015 ...
... Medical imaging facilities can now submit anonymized dose information ... (DIR) allowing them to compare their dose indices to ... national benchmarks. Participating facilities receive periodic feedback comparing their dose ... adjustments to lower dose received from scans. ...
... more than 35 years experience in breast imaging, has been ... of Radiology (ACR), the organization,s highest honor given for distinguished ... award will be presented to Bassett May 15 at the ... proud to be recognized by my peers for my contributions ...
... A Nordic multicentre study, headed by researchers from Karolinska ... using synthetic mesh can be more effective than traditional ... restored genital anatomy and more efficient symptom relief, although ... study is published in the renowned scientific periodical The ...
... that the vast majority of patients at high risk for ... statins as prescribed. That,s especially unfortunate, because the same study ... length of those patients, lives. "We found that only ... taking their prescribed dose on a regular basis after one ...
Cached Medicine News:Health News:Treating HIV-infected people with antiretrovirals significantly reduces transmission to partners 2Health News:Treating HIV-infected people with antiretrovirals significantly reduces transmission to partners 3Health News:Treating HIV-infected people with antiretrovirals significantly reduces transmission to partners 4Health News:ACR launches dose index registry 2Health News:UCLA cancer researcher wins prestigious Gold Medal from the American College of Radiology 2Health News:Synthetic mesh can improve outcome of prolapse surgery 2Health News:Study: Most at-risk patients don't adhere to statin treatment, despite real benefits 2
The Optima III line of laparoscopic hand instruments provides a well-crafted set of instruments designed for strength and durability....
The Snap-In Snap-Out-II Tip Inserts offer a large variety of configurations....
Single-action, stainless steel micro biopsy forceps....
The Optima III 45 cm line of laparoscopic hand instruments is ideal for operative laparoscopic/endoscopic procedures or when a longer instrument is needed....
Medicine Products: